PSMA: a potential therapeutic target in RCC

Prostate-specific membrane antigen (PSMA) is expressed by prostate cancer cells as well as endothelial cells within the neovasculature of a number of malignancies including renal cell carcinoma (RCC). PET radiotracers that target PSMA have shown great promise for imaging RCC. Agents that target PSMA also have the potential to be used as therapeutics in patients with this malignancy.